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Bacterial resistance to antibiotics is one of the biggest 
threats to global health today. Therefore, there is a pressing 
need for new antibiotics. In this study, we examined four 
fungal strains for novel Lipid II-targeting antibiotic 
compounds. To do this, we analyzed fungus-extracted 
fractions by antibacterial activity assays in which Lipid II 
was included to detect antagonism, TLC and LC-MS. We 
identified eighteen Lipid II-targeting active fractions. 
Further purification and characterization of one active 
compound suggested a hydrophobic nature and a 
corresponding m/z value of 805 or 1300. Further research 
should elucidate the structure of the compound.  
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*In this paper, details on fungal species and strains have been 
removed for confidentiality.  
 
INTRODUCTION 
The widespread and inappropriate use of antibiotics has 
caused the emergence of multidrug resistant bacteria. As a 
result, patient morbidity and mortality rates have 
increased1. According to the World Health Organization, 
these resistant bacteria are one of the biggest threats to 
global health today. However, despite the pressing need for 
new antibiotics, the introduction of new antibiotics has 
decreased significantly over the past decades2.  
For a potential new antibiotic it is of importance that it acts 
on a specific bacterial target to avoid toxicity for 
mammalian cells. A target that has proven to be successful 
is Lipid II, a bacteria-specific membrane component that 
is involved in peptidoglycan synthesis3. Peptidoglycan, the 
main component of the cell wall, is a crosslinked polymer 
that provides bacteria with the structural rigidity needed to 
cope with osmotic pressure differences4,5.  In 
peptidoglycan synthesis, Lipid II carries the peptidoglycan 
building blocks from the cytoplasm to the periplasm. 
Therefore, Lipid II is essential for bacterial survival.   
The importance of Lipid II, in combination with its 
specificity for bacteria and its accessibility as a membrane 
compound, makes Lipid II an effective target for 
antibiotics. This is illustrated by the multitude of existing 
Lipid II-targeting antibiotics (e.g. several glycopeptides 
such as vancomycin and ramoplanin, several lantibiotics 
such as nisin, etc.). It is striking that these antibiotics differ 
from each other in many aspects, such as interacting site, 
affinity and mechanism6. This indicates that there are many 
opportunities for antibiotic attack involving Lipid II.   
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Moreover, the effectiveness of Lipid II as target is 
illustrated by the reliability of Lipid II-targeting antibiotics 
in treating bacterial infections. In fact, vancomycin has 
long been used as a drug of last resort for treating 
Methicillin-resistant Staphylococcus aureus (MRSA)7. 
This can be explained by the fact that Lipid II is a non-
proteinaceous target and can therefore not be altered 
directly through mutations. Unfortunately, bacterial 
strains resistant to vancomycin have arisen in the last 
decades. In the recent past, MRSA strains highly resistant 
to vancomycin have been described in clinical literature8.  
Therefore, there is a need for novel classes of antibiotics. 
In this study, we focused on finding new Lipid II-targeting 
antibiotics. As fungi have been valuable sources of 
antibiotic compounds in the past9, we opted to use fungi as 
our starting point. We approached our search by extracting 
compounds from four fungal strains, fractionating the 
compounds and screening for activity against 
Staphylococcus simulans, a bacterium from the same 
genus as MRSA that is safe to work with in the lab. Active 
fractions were tested for Lipid II activity by antagonism 
experiments, followed by further identification and 





Fungi were kindly provided by Jan Dijksterhuis 
(Westerdijk Institute). UDP-N-Acetylmuramyl-
pentapeptide (lysine form) was derived from 
Staphylococcus simulans. UDP-N-Acetylglucosamine 
was purchased from Sigma Aldrich. All other chemicals 
used were of analytical grade or better.    
 
Lipid II synthesis and purification 
Lipid II (lysine form) was synthesized and purified as 
described by Breukink et al.10, except that solely 
undecaprenyl was used instead of varying prenylchain 
lengths.   
 
Fungal extractions  
Fungus A, Fungus B, Fungus C  and Fungus D* were 
grown for one and two weeks on different solid media: 
Malt Extract Broth (MEB), Yeast Extract with 
Supplements (YES) and/or Czapek Yeast Agar (CYA). 
The agar plates were cut in pieces and extracted two times 
with 40 mL ethyl acetate under sonication. In the 
extraction, the agar of the one and two weeks old plates of 
the same fungus and medium were combined. The extracts 
were filtered through cellulose filters (Whatman) to purify 
the extracts from possible spores. Ethyl acetate was 
removed by rotary evaporation under vacuum. The dried 






Table 1. Amount of dry matter obtained for each fungus 
and volume of methanol it was dissolved in.  





A MEB 21.6 2.0 
A YES 136.3 3.0 
B MEB 33.6 2.0 
C MEB 15.6 1.0 
C YES 63.3 3.0 
D MEB 9.4 1.0 
D CYA 12.4 1.0 
  
 
Fractionation of fungal extracts  
A volume of fungal extract containing 8 mg dry matter was 
applied to a C18 reversed phase column (2×2.5 cm). Elution 
was performed stepwise with 10%, 30%, 50%, 70% and 
90% methanol in water. The collected fractions were dried 
and resuspended in 200 µL methanol.  
 
Activity screens 
The fungal extract fractions were tested by spotting 2 and 
4 µL on 1.6% tryptic soy broth (TSB) agar plates 
containing Staphylococcus simulans. Active fractions were 
selected and screened for Lipid II-specific activity. 0, 1, 2 
and 5 nmol Lipid II, dissolved in 50 mM Tris-HCl 0.1% 
Triton X-100 buffer pH 7.5, were spotted on new bacterial 
plates at a distance corresponding to the halo size of the 
initial activity screen. The bacterial plates were placed in a 
30oC stove for ~16 hours before analysis.   
 
Thin layer chromatography (TLC) 
All fractions were filtered over a 4 mm syringe driven filter 
unit (Millex). 5 µL of each fraction was put on a reversed 
phase TLC plate (Silica gel 60 RP-18 F254s; Merck) using 
the Linomat 5 (Camag) and developed in 70% methanol in 
water at T=20oC and rH=57% using the Automatic 
Developing Chamber 2 (Camag). The bands were 
visualized under UV at 254, 302 and 365 nm. For further 
analysis, some fractions were again put on reversed phase 
TLC and developed in 80% methanol in water. The silica 
of interesting bands was scratched off and extracted twice 
in 100 µL methanol/2-propanol (1:1). The extracts were 
filtered over a 4 mm syringe driven filter unit (Millex), 
dried and resuspended in 5 µL methanol. The extract were 
then tested using activity screens as described above.  
 
Liquid chromatography-mass spectrometry (LC-MS) 
The LC-MS analysis was performed using a LCQ Deca XP 
mass spectrometer (Thermo Finnigan), coupled to a 
Surveyor autosampler and Surveyor pump (Thermo 
Finnigan). Compounds were first trapped on a Gemini µm 
NX-C18 110 Å LC column (150×2 mm; Phenomenex) 
using 0.1% TFA in water and 2-propanol (19:1). Elution 
was performed with a flow rate of 200 µL/min and an 
increasing concentration of 2-propanol as follows: 5% 2-
propanol for 10 min, from 5% to 100% 2-propanol in 30 
min (linear gradient) and finally 100% 2-propanol for 10 
min. The column effluent was introduced into the ESI-
source of the mass spectrometer, which was set to positive 
polarity. Mass spectra were acquired and processed with 




In this study, we examined four fungal strains for Lipid II-
specific antibiotic activity. Fungi and growth media were 
chosen based on previous research in our lab, which 
showed that different strains, and even the same strain 
grown on a different medium, produced different 
compounds11. In line with this research, we observed clear 
differences between the appearances of the fungi 
depending on strain and medium (Figure 1). To obtain 
fungal compounds, we extracted cut-up pieces of agar with 
ethyl acetate. In this way, we obtained seven fungal 
extracts. These extracts were separated into fractions of 
different hydrophobicity using a reversed phase C18 
column, which was eluted stepwise with increasing 
concentrations of methanol. The obtained fractions were 
then concentrated and used for further analysis.  
First, we investigated which fractions contained antibiotic 
activity. To do this, we spotted 2 and 4 µL of the fraction 
on agar plates containing Staphylococcus simulans. If a 
fractions contained antibiotic activity this could be seen 
because a halo, where no bacteria grew, arose after putting 
the agar plate in the stove overnight. Representative 
images of fractions showing activity are shown in Figure 
2 (left column). In total, we found activity in 35 of the 74 
tested fractions.  
We then analyzed for which fractions this activity was 
Lipid II-specific. To do this, 0, 1, 2 and 5 nmol of Lipid II 
were spotted on the predicted edge of the halo before 
Figure 2. Representative images of fractions showing no Lipid II 
antagonism and fractions showing Lipid II antagonism. 0, 1, 2 and 5 
indicate the amount of Lipid II spotted (nmol). Images were taken from 
fraction 70-1 of Fungus B on Malt Extract Broth (top) and from fraction 
90-1 of Fungus B on Malt Extract Broth (bottom).  
Figure 1. Pictures of the investigated fungi. All pictures were taken 
after growing fungus for 2 weeks. MEB = Malt Extract Broth, YES = 
Yeast Extract with Supplements, CYA = Czapek Yeast Agar.  
spotting the active fraction. This way, the antibiotic 
activity of the fungal extract was antagonized by Lipid II 
if the activity was Lipid II-specific. As a result, the round 
halo form was disturbed. This could be seen on the agar 
plates after growing the bacteria overnight (Figure 2, 
bottom right). Of the 35 fractions tested, eighteen showed 
clear Lipid II-antagonism, implying that the activity of 
these fractions was Lipid II-targeting. The amount and 
hydrophobicity of Lipid II active fractions differed for 
different fungi and media, confirming the importance of 
growth medium and fungal strain for the production of 
antibiotic compounds.  
To learn more about the content of the Lipid II-active 
fractions, we analyzed all fractions using reversed phase 
thin layer chromatography (TLC). The TLC plates were 
analyzed under UV light. The colour, height and number 
of bands for each fraction differed greatly for each 
fungus/medium (results not shown), again showing the 
role of strain and medium for antibiotic production. One 
fraction (Fungus B, 90-1) was of particular interest to us, 
as it contained strong antibiotic activity (Figure 2, bottom 
row) and the TLC plate showed one bright yellow band 
that was absent in surrounding fractions (Figure 3, 90-1). 
To investigate whether this band contained the antibiotic 
activity, we purified the band from TLC. For this, a new 
TLC plate of the Fungus B 90-1 fraction was made and 
developed in 80% methanol instead of 70%. Now, a red 
band appeared that was not visible in the previous TLC 
plate (Figure 4A).  
 
To find out whether the red band, yellow band or neither 
contained the antibiotic activity, we scratched both 
compounds off and extracted the silica using methanol/2-
propanol (1:1). To prevent contamination of the red band 
in the yellow and vice versa, the silica was scratched off in 
such a way that the yellow band was pure and the red 
contained yellow contaminations. The extracts were then 
tested for antibiotic activity by spotting the extract on agar 
plates containing S. simulans as described above. Both 
extracts showed activity, although the halo for the yellow 
extract was clearer (Figure 4B and 4C). From this 
experiment we concluded that the yellow band contained 
the antibiotic activity. The weak activity seen for the red 
band can be explained by the yellow contaminations that 
were present.  
We next set out to learn more about the active compound. 
To do this, we performed liquid chromatography-mass 
spectrometry (LC-MS). In the LC-MS experiment, elution 
form the reversed phase column was performed with an 
increasing concentration of 2-propanol. Comparing the 
mass spectrum of the 90-1 fraction to a blanc resulted in 
several m/z values that were more abundant in the 90-1 
fraction (Figure 5). Especially the peaks at m/z 805 and 
1300 stood out, suggesting these peaks belonged to the 
active compound. The 805 and 1300 peaks started eluting 
from ~36 min and ~37 min respectively, when the 2-
propanol concentration was almost 100%. This indicated a 
hydrophobic nature of the active compound. This is in line 
with the fact that the active compound was located in the 
90% methanol fraction of the initial fractionation. 
 
DISCUSSION AND IMPLICATIONS 
In this paper, we have found fungal compounds with 
potential of being developed into novel antibiotics using 
antibacterial activity assays. Fungi have proven useful for 
the production of antibiotic compounds in the past9 and 
Figure 3. Thin layer chromatography (TLC) plate obtained from 
fractions of Fungus B on Malt Extract Broth. 10, 30, 50, 70 and 90 
indicate the concentration of methanol (%) in water of the fraction. 1 and 
2 indicate the first and second collected fraction. Picture of TLC was 
taken under UV light (λ = 302 nm).  
Figure 5. Averaged mass spectra of liquid chromatography eluents. 
Averaged mass spectra of eluents that eluted from 36 min until 46 min 
from a blanc (top) and the 90-1 fraction of Fungus B (bottom).  
Figure 4. Analysis of 
Fungus B fraction 90-1.
A) TLC plate of the 90-1 
fraction of Fungus B
developed in 80% 
methanol. λ = 365 nm. 
Arrow indicates red band 
that was not visible after 
development in 70% 
methanol. B) Activity 
assay done with extract 
of red band. C) Activity 
assay done with extract 
of yellow band.  
this was also the case in this study, as 35 of the 74 tested 
fractions contained antibiotic activity. The activity of 
eighteen of these fractions was also Lipid II-targeting, as 
became clear from antagonism experiments.  
One active compound, located in fraction 90-1 of Fungus 
B, has been further characterized using thin layer 
chromatography and liquid chromatography-mass 
spectrometry (LC-MS). Our results suggest potential 
masses and a hydrophobic active compound. In the LC-MS 
experiment, the Fungus B 90-1 fraction was compared to a 
blanc. It was found that m/z values of 805 and 1300 may 
correspond to the active compound. However, these peaks 
can also be seen in the spectrum recorded for the blanc 
(although with a lower relative abundance). This 
observation can be explained by the fact the column was 
used several times prior to recording the blanc to record 
Fungus B 90-1 fractions. Since the active compound is so 
hydrophobic, some of the active compound could have still 
been present on the column when recording the blanc 
spectrum. Although more research is required to determine 
the mass with certainty and to elucidate the structure of this 
compound, it may eventually be developed further into an 
antibiotic that can be used in the clinic. 
Next to having detected promising compounds with 
potential to be used as antibiotics, this study provides a 
simple yet functional approach in the search for novel 
antibiotics. There is still a large variety of fungi that can be 
investigated in this way, thus providing many 
opportunities for finding new antibacterial compounds. 
This is important to be able to meet the pressing need for 
new antibiotics that is a major health problem today and 
will likely remain so in the future. 
In spite of the promise that fungal derived compounds 
hold, there is one challenge that needs to be solved. As can 
be seen from the TLC plates and the differences in activity, 
the medium on which a fungus is grown has an influence 
on the compounds the fungus produces. Moreover, we 
have experienced in our lab that there can even be 
differences between two fungi of the same strain that are 
grown on the same medium. More research needs to be 
conducted to find stable growth conditions in which more 
or less the same compounds are reproducibly produced by 
the fungus. Because of this, it is important that our 
experiments are repeated to see if the same results are 
obtained. 
In addition to finding stable growth conditions, finding 
growth conditions in which the natural competitors of 
fungi (e.g. bacteria) are present may provide a way to make 
the fungus produce even more substances that have 
potential as antibiotic. This would be an interesting 
concept for future research. 
 
CONCLUSION 
In this study, we set out to find novel Lipid II-specific 
antibiotic compounds from fungi. From four fungal strains,  
we identified eighteen fractions that contained Lipid II-
specific antibiotic activity. One of these fractions, 90-1 
from Fungus B,  was further characterized. We found some 
important properties of the active molecule: the band 
corresponding to the molecule on TLC, its hydrophobic 
nature and possible molecular weights. From these results, 
we conclude that we have successfully detected Lipid II-
targeting antibiotic compounds. Further research should 
elucidate what the structure of these compounds is and 
 
whether these compounds could be developed into 
antibiotics for clinical use. Moreover, the method used in 
the study provides a model for analysis of other fungi. 
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